IL187190A0 - Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors - Google Patents

Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Info

Publication number
IL187190A0
IL187190A0 IL187190A IL18719007A IL187190A0 IL 187190 A0 IL187190 A0 IL 187190A0 IL 187190 A IL187190 A IL 187190A IL 18719007 A IL18719007 A IL 18719007A IL 187190 A0 IL187190 A0 IL 187190A0
Authority
IL
Israel
Prior art keywords
metabotropic glutamate
oxadiazole derivatives
positive allosteric
glutamate receptors
allosteric modulators
Prior art date
Application number
IL187190A
Other languages
English (en)
Original Assignee
Addex Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addex Pharma Sa filed Critical Addex Pharma Sa
Publication of IL187190A0 publication Critical patent/IL187190A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL187190A 2005-05-18 2007-11-06 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors IL187190A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0510142.3A GB0510142D0 (en) 2005-05-18 2005-05-18 Novel compounds A1
PCT/IB2006/001674 WO2006123249A2 (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Publications (1)

Publication Number Publication Date
IL187190A0 true IL187190A0 (en) 2008-02-09

Family

ID=34708380

Family Applications (1)

Application Number Title Priority Date Filing Date
IL187190A IL187190A0 (en) 2005-05-18 2007-11-06 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Country Status (17)

Country Link
US (1) US20090197897A1 (enExample)
EP (1) EP1896463A2 (enExample)
JP (1) JP2008540634A (enExample)
KR (1) KR20080031676A (enExample)
CN (1) CN101218232B (enExample)
AU (1) AU2006248649B2 (enExample)
BR (1) BRPI0610681A2 (enExample)
CA (1) CA2608012A1 (enExample)
EA (1) EA015263B1 (enExample)
GB (1) GB0510142D0 (enExample)
IL (1) IL187190A0 (enExample)
MX (1) MX2007014405A (enExample)
NO (1) NO20076479L (enExample)
NZ (1) NZ564253A (enExample)
UA (1) UA92496C2 (enExample)
WO (1) WO2006123249A2 (enExample)
ZA (1) ZA200710277B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
AU2006248655A1 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted Oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
CA2696016A1 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2009099177A1 (ja) * 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
EP2421370A4 (en) * 2009-04-23 2012-12-12 Merck Sharp & Dohme 2-alkyl-piperidine-mGluR5 receptor MODULATORS
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
WO2012101292A1 (es) * 2011-01-25 2012-08-02 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
SG11201502493XA (en) 2012-10-10 2015-04-29 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
ES2696708T3 (es) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Uso de derivados de bencimidazol-prolina
JP6668329B2 (ja) 2015-03-25 2020-03-18 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
EP3914592A1 (en) * 2019-01-25 2021-12-01 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
EP4210824A1 (en) * 2020-09-09 2023-07-19 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
IL291418B2 (en) 2022-03-16 2024-05-01 Anima Biotech Inc Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
US6440996B1 (en) * 1998-10-07 2002-08-27 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
WO2001002375A1 (en) * 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
KR100875222B1 (ko) * 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
US20020002171A1 (en) * 2000-01-28 2002-01-03 Chalquest Richard R. Materials and methods for killing nematodes and nematode eggs
IL157491A0 (en) * 2001-02-21 2004-03-28 Nps Pharmeceuticals Inc Heteropolycyclic compounds and pharmaceutical compositions containing the same
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
JP4347050B2 (ja) * 2001-09-21 2009-10-21 田辺三菱製薬株式会社 ３−置換−４−ピリミドン誘導体
DK1427709T3 (da) * 2001-09-21 2006-04-03 Mitsubishi Pharma Corp 3-substituerede 4-pyrimidonderivater
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
KR20050033070A (ko) * 2002-08-09 2005-04-08 아스트라제네카 에이비이 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
CA2495179A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
PL375964A1 (en) 2002-09-06 2005-12-12 Janssen Pharmaceutica, N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
NZ542680A (en) * 2003-03-12 2008-08-29 Kudos Pharm Ltd Phthalazinone derivatives
WO2004087048A2 (en) 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
SG149900A1 (en) * 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
CN101048397A (zh) * 2004-09-29 2007-10-03 三菱制药株式会社 作为τ蛋白激酶1抑制剂的6－（吡啶基）－4－嘧啶酮衍生物
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
AU2006248655A1 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted Oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Also Published As

Publication number Publication date
CN101218232B (zh) 2012-06-27
US20090197897A1 (en) 2009-08-06
GB0510142D0 (en) 2005-06-22
MX2007014405A (es) 2008-04-21
WO2006123249A2 (en) 2006-11-23
WO2006123249A3 (en) 2007-02-08
CA2608012A1 (en) 2006-11-23
NO20076479L (no) 2008-01-29
UA92496C2 (ru) 2010-11-10
JP2008540634A (ja) 2008-11-20
AU2006248649A1 (en) 2006-11-23
KR20080031676A (ko) 2008-04-10
EA015263B1 (ru) 2011-06-30
ZA200710277B (en) 2009-03-25
AU2006248649B2 (en) 2012-04-26
EP1896463A2 (en) 2008-03-12
EA200702468A1 (ru) 2008-06-30
BRPI0610681A2 (pt) 2010-07-20
CN101218232A (zh) 2008-07-09
NZ564253A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
ZA200710277B (en) Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
IL187186A0 (en) Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
IL187189A0 (en) Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
IL179692A0 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
IL189617A0 (en) Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
ZA200801641B (en) Chromenones and their use as modulators of metabotropic glutamate receptors
IL181742A0 (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
ZA200908285B (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842
PL1994004T3 (pl) 1,4-Dipodstawione pochodne 3-cyjano-pirydonu i ich zastosowanie jako pozytywnych allosterycznych modulatorów receptorów MGLUR2
IL219149A0 (en) Novel oxime derivatives and thier use as allosteric modulators of metabotropic glutamate receptors
IL177524A0 (en) Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
IL201995A0 (en) Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
IL207332A0 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
ZA200710278B (en) Substituted Oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0507793D0 (en) Allosteric modulators of glutamate receptors
HK1102330A (en) Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors
HK1102329A (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
HK1150600A (en) Amide derivatives as positive allosteric modulators and methods of use thereof
HK1142061A (en) Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
HK1142609A (en) Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators - 841
HK1126215A (en) Substituted 4-amino-quinazoline derivatives as regulators of metabotropic glutamate receptors and their use for producing drugs